Analysis of the efficacy and safety of PD-1 inhibitor combined with first-line chemotherapy on advanced lung adenocarcinomas with negative driver gene mutations
Objective To investigate the efficacy and safety of programmed cell death protein 1(PD-1)inhibitor combined with first-line chemotherapy on advanced lung adenocarcinomas with negative driver gene mutations.Methods Medical records of 60 patients with advanced lung adenocarcinomas with negative driver gene mutations admitted from January 2019 to December 2021 were retrospectively analyzed.According to different treatment methods,30 patients receiving pemetrexed combined with cisplatin were included in the control group,and 30 receiving pemetrexed,cisplatin combined with PD-1 inhibitor(Sintilimab)were included in the observation group.Clinical efficacy before treatment and at 30 days of treatment,including the objective response rate(ORR)and disease control rate(DCR)were compared between groups.Immune function indicators,including CD4+T cells,CD8+ T cells and CD4+/CD8+ ratio were compared.Tumor markers,including carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)were compared.The incidence of adverse events,including nausea,granulocytopenia,abnormal liver function,thyroid dysfunction,pneumonia,rash and thrombocytopenia was compared.Results The ORR of the observation group was significantly higher than that of the control group(P＜0.05).There was no significant difference in DCR between the two groups(P＞0.05).After treatment,CD4 T cells,CD8 T cells and CD4/CD8 ratio in the observation group were significantly higher than before treatment and higher than that of the control group(P＜0.05).After treatment,the levels of CYFRA21-1 and CEA in both groups decreased,which were significantly lower in the observation group than those of the control group(P＜0.05).Case number of adverse events like thyroid dysfunction,pneumonia and rash was significantly greater in the observation group than that of the control group(P＜0.05).Conclusion PD-1 inhibitor combined with first-line chemotherapy can effectively improve the immune function and lower tumor markers with a definite therapeutic effect on patients with advanced lung adenocarcinomas with negative driver gene mutations.
lung adenocarcinomanegative driver gene mutationsprogrammed cell death protein 1(PD-1)inhibitorchemotherapyimmune function
NETL
NSTL
万方数据
维普
